Study Reveals Magnesium Isoglycyrrhizinate's Role in Alleviating Alcohol-Associated Liver Disease
Recent research has highlighted the potential of magnesium isoglycyrrhizinate (MgIG) in treating alcohol-associated liver disease (ALD). The study, conducted using both in vivo and in vitro models, demonstrates that MgIG can ameliorate key features of ALD, such as hepatic steatosis, inflammation, and apoptosis. The research identifies IDI1, an enzyme involved in cholesterol synthesis, as a critical mediator of MgIG's hepatoprotective effects. The study further reveals that MgIG targets the HSD11B1-SREBP2-IDI1 axis, providing a mechanistic link between lipid metabolism and ALD pathogenesis. By binding to HSD11B1, MgIG inhibits its activity, leading to reduced SREBP2 activation and subsequent downregulation of IDI1, which contributes to improvements in liver health.